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Identical mutation associated 
with distinct clinical phenotypes 
of Friedreich’s ataxia: case report
Maša Malenica1, Monika Kukuruzović1, Suzana Bitanga1, Goran Krakar2, 
Bernardica Valent1, Ljerka Cvitanović-Šojat1
Friedreich’s ataxia is an autosomal recessive disease and the most frequent inherited ataxia. The disease is characterized by 
expression of the unstable GAA trinucleotide repeat expansion located in the fi rst intron of the FXN gene on chromosome 9. Clini-
cally, it is presented by progressive gait and limb ataxia, absent refl exes with positive Babinski, and cardiomyopathy with no diff er-
ence regarding race and gender. Our patients are teenage siblings in whom analysis of DNA confi rmed both alleles with full muta-
tion in the FXN gene that codes for frataxin. Even though both siblings have full mutation and are both in the same age group, their 
clinical presentation and course of the disease are rather diff erent. The sister has almost all typical neurologic signs of Friedreich’s 
ataxia with progressive course despite supportive therapy. The brother shows only hypertrophic cardiomyopathy with no neuro-
logic or skeletal disturbances so far. It is possible that other factors may also play an important role in the clinical presentation and 
course of Friedreich’s ataxia. The cases of our patients prove that it is not advisable to foresee the clinical course based solely on the 
number of repeats.
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INTRODUCTION
Friedreich’s ataxia (FA or FRDA) is an autosomal recessive 
spinocerebellar disorder that has a slow, degenerative 
course. It aff ects one per 50 000 people and is the most fre-
quent inherited ataxia. Friedreich’s ataxia is characterized by 
progressive gait and limb ataxia, with no diff erence regard-
ing race and gender. Genetically, it is identifi ed by expres-
sion of the unstable guanidine adenine adenine trinucle-
otide (GAA) repeat expansion in the fi rst intron of the FXN 
gene on chromosome 9. Most patients are homozygous for 
the expansion of GAA triplet repeat within the FXN gene. A 
great majority of patients with FA (about 94%) are ho-
mozygous for the GAA trinucleotide, while only a small per-
centage (about 6%) are compound heterozygotes for GAA 
expansion and frataxin point mutation responsible for the 
formation of abnormal protein as a possible source of diff er-
ent clinical presentation (1). The expanded GAA repeat is 
thought to result in frataxin defi ciency by interfering with 
transcription of the gene by adopting an unstable helical 
structure. The larger the number of repeats, the more pro-
found is the reduction in frataxin expression (2). The age at 
disease onset, severity, progression speed, and neurologic 
involvement vary with the number of repetitive GAA se-
quences (3). The broad clinical spectrum includes late-on-
set FA (LOFA) and FA with retained refl exes (FARR).
There are many issues regarding frataxin. Studies have 
shown that frataxin is a mitochondrial protein important for 
normal production of cellular energy. Defect in frataxin re-
sults in abnormal accumulation of iron in mitochondria, 
hence leading to excess production of free radicals. As body 
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cells and tissues have diff erent sensitivity to frataxin defi -
ciency, cells normally requiring and producing greater 
amounts of frataxin tend to be most aff ected by FA. Some of 
those are sensory neurons in the dorsal root ganglion, which 
highly express the frataxin gene, as well as myocardial mus-
cle fi bers which also require larger amounts of frataxin than 
other tissues. Studies in patients with FA have shown mito-
chondrial iron-like deposits in heart muscle not present in 
healthy hearts. Along with histology in approximately 65% 
of patients with FA there are abnormal electrocardiography 
(ECG) fi ndings, mostly T wave inversions and concentric 
ventricular hypertrophy (4). In over 90% of patients, there 
will be absent sensory nerve action potentials, while nerve 
conduction velocity studies might be only mildly reduced. 
Expected are abnormal fi ndings in brainstem auditory and 
visual evoked potentials in about 75% of patients with FA. 
Unfortunately, chronic progression of the disease will cause 
patients to lose the ability to walk about 15 years of the on-
set of symptoms. In patients with predominant heart dis-
ease, especially if coupled with diabetes (as in 10% of pa-
tients), death tends to occur earlier than expected.
Considering clinical diagnosis, progressive limb and gait 
ataxia developing before the age of 25 is highly indicative of 
FA. Children with delayed ability to walk, diffi  culty in stand-
ing steadily, and in running should be examined further. In 
FA, in addition to typical cerebellar ataxia, there is also a loss 
of joint position sense, hence children tend to assume a 
wide-based stance. Aff ected children will almost always 
have diminished or absent patellar and ankle refl exes. 
Sometimes, these symptoms become more pronounced 
after an immune episode such as febrile illness. Initially it 
may be possible to notice fi ne hand tremor or problems in 
drawing and writing in a young child, as hands tend to be 
aff ected earlier than legs. Dysarthric speech may be attrib-
utable to young age or other issues and overlooked as an 
important early symptom.
As always, not only neurologic symptoms lead to diagnosis, 
and upon physical examination it may be possible to fi nd 
pes cavus and kyphoscoliosis. Some of the children com-
plain of tiredness and loss of weight, as swallowing be-
comes aff ected with weakening of facial muscles. A rather 
unspecifi c but often present symptom is peripheral cyano-
sis of lower limbs, as well as horizontal nystagmus. A very 
serious and mostly lethal symptom is concentric hyper-
trophic cardiomyopathy including myocarditis, tachycardia, 
and hypertension (5). Emotional lability may be expected, 
especially with progression of the disease course. For as-
sessing the course of ataxia, it is recommended to use the 
International Cooperative Ataxia Rating Scale (ICARS).
So far, no medication altered the progressive course of the 
disease, even though the search for experimental drugs in-
creasing the amount of frataxin is very active. Prior to start-
ing FA treatment, the level of vitamin E needs to be evalu-
ated as its defi ciency caused by mutation on chromosome 
8 creates a very similar clinical picture and can be treated. 
Considering the formation of free radicals by excess mito-
chondrial iron, coenzyme Q is recommended as an antioxi-
dant with the possible eff ect on heart dysfunction. Further-
more, studies have shown some improvement of neuro-
logic and cardiac function with idebenone, which is 
recommended in conjunction with physical therapy.
CASE REPORT
Our fi rst patient was a 15-year-old girl. Her family and per-
sonal history are rather uneventful. Her psychomotor devel-
opment has been normal, and she did not suff er from any 
serious illness. She was admitted for diagnostic evaluation 
of clumsiness and transitory tremor of hands, which be-
came more visible after a short febrile illness. On initial phys-
ical examination, she had scoliosis (and wore thoracic or-
thosis), pes cavus, and wide based stance. She had heart 
murmur II/VI. Cardiac examination and tests (ECG and ultra-
sonography) confi rmed concentric hypertrophic cardiomy-
opathy with hypertension. Neurological examination 
showed mild ataxia, horizontal nystagmus and mild tremor 
of the hands. Electromyoneurography (EMNG) indicated full 
loss of nerve conduction potentials with signs of demyeli-
nation and borderline velocities on lower extremities. Ge-
netic analysis of DNA for FA confi rmed our clinical suspicion 
of FA, as she has full mutation with 1095/1095 continuous 
GAA triplets. Her therapy included the angiotensin-convert-
ing enzyme (ACE) inhibitor, idebenone and coenzyme Q 
with physical therapy. Due to the progression of scoliosis, 
she had corrective spine surgery, which allowed her to walk 
more easily. Despite all supportive therapy administered for 
three years of the diagnosis, the score on ICARS is increasing 
(6). Her walking capacity from being widely based has now 
become impossible without support of the wall for a 10-
meter test or aid of another person when turning. Her gait 
speed has now become markedly reduced and spastic. She 
has lost the capacity to stand with feet together, but is able 
to stand in natural position without support, with moderate 
sway. The spread of her feet in standing position with eyes 
open increased from 25 cm to 35 cm. In the fi nger to nose 
test, she now has segmented movements and moderate 
dysmetria with intention tremor. Her speech from having 
mild modifi cation of fl uency is now considerably slow and 
dysarthric with slurring, but most words are still understand-
able.
Her younger brother, now aged 14, has never had any simi-
lar clinical or neurologic symptoms. On outpatient cardiol-
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ogy examination, there was hypertension and concentric 
hypertrophic cardiomyopathy with inversion of T waves on 
ECG. His FXN genotype has full mutation with 669/669 GAA 
repeats. His neurologic status and EMNG have been unre-
markable for two years now. However, repeated cardiolo-
gist’s examinations revealed progression of cardiomyopathy 
as well as of hypertension. He is now also receiving ACE in-
hibitor, coenzyme Q and idebenone therapy. 
DISCUSSION
We present our patients, teenage siblings with FA, whose 
number of GAA (1095/1095 and 669/669) classifi es them 
into the same category of disease severity, i.e. full mutation 
(66-1700 GAA). The sister has almost typical clinical devel-
opment and presentation of the disease with the physical 
signs of scoliosis, pes cavus and cardiomyopathy, and neuro-
logic signs of tremor, nystagmus and ataxia. On the other 
hand, her brother had only worsening of cardiomyopathy 
and hypertension, with normal neurologic status. Such dif-
ferent clinical presentations would be expected in com-
pound heterozygotes or in homozygotes with premutation 
alleles, which is not the case in our patients (2, 7). Our con-
cern with the brother is the possibility of sudden cardiac 
death in childhood, as it may be diffi  cult to control the pro-
gression of cardiac involvement (8). Since the sister has lost 
patellar refl exes, it could be arguable that the brother has 
FARR variant (with retained deep tendon refl exes), while she 
has the classic variant of the disease. This only supports the 
idea that FARR is just a phenotype variability of the same 
genetic disease (9). It may also be that the sister as the more 
severely aff ected sibling is harboring larger expansions in 
spinal cord and other aff ected tissues (10). Variable clinical 
expressions have been described in siblings in whom the 
disease onset occurred as late as 60-70 years. However, 
these cases are an excellent proof that small homozygous 
expansions with approximately 120-130 GAA repeats, which 
were interrupted either with GAAGAG, GAAGGA or GAA-
GAAAA sequences, will have diff erential phenotype display 
(2). Profound cytoskeleton anomalies in patients with FA 
such as marked spinal scoliosis with progressive course re-
quiring spinal surgery in the sister may also be explained by 
gene silencing which spreads in cis over the PIP5K1B gene 
in cells of FRDA patients correlating with expanded GAA re-
peat size (11). 
CONCLUSION
Phenotypic diversity of FA is expanding, but the progressive 
course is a constant. So far, no gender diff erences have been 
described in the literature. The age at onset and the struc-
ture of GAA repeat expansion play an important role in de-
termining clinical features and diff erential diagnosis of FA, 
but other factors such as somatic mosaicism, repeat inter-
ruptions, modifying mutations and environmental factors 
must also be considered (7). Therefore, in familial FA, the dis-
ease course in relatives should not be predicted solely from 
the repeat length.
Abrreviations:
GAA - guanidine adenine adenine
FA or FRDA - Friedreich’s ataxia
LOFA - late-onset FA
FARR - FA with retained refl exes
ICARS - International Cooperative Ataxia Rating Scale
EMNG - Electromyoneurography
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S A Ž E T A K
Identična mutacija povezana s različitim fenotipom 
Friedreichove ataksije
M. Malenica, M. Kukuruzović, S. Bitanga, G. Krakar, B. Valent, Lj. Cvitanović-Šojat
Friedreichova ataksija je autosomno recesivna bolest koja je najčešća među nasljednim ataksijama. Bolest je karakterizirana 
 ekspresijom nestabilne ponavljajuće GAA sekvence trinukleotida koja se nalazi u prvom intronu gena FXN na 9. kromosomu. Klinički 
se najčešće prikazuje progresivnom ataksijom, arefl eksijom uz pozitivan Babinski te kardiomiopatijom, bez obzira na rasu i spol. Naši 
su bolesnici tinejdžeri brat i sestra, kod kojih je analiza DNA potvrdila oba alela s punom mutacijom u genu FXN koji kodira frataksin. 
Iako oboje imaju punu mutaciju i oboje su u istoj dobnoj skupini, njihov klinički izražaj i tijek bolesti su vrlo različiti. Sestra ima gotovo 
sve tipične neurološke znakove Friedreichove ataksije, uz progresivan tijek unatoč potpornoj terapiji. Brat zasad pokazuje isključivo 
hipertrofi čnu kardiomiopatiju bez neuroloških ili koštanih poremećaja. Moguće je da i drugi čimbenici imaju važnu ulogu u kliničkoj 
prezentaciji i tijeku Friedreichove ataksije. Primjer naših bolesnika potvrđuje da nije preporučljivo predviđati klinički tijek isključivo na 
broju ponavljajućih sekvencija.
Ključne riječi: Friedreichova ataksija; blizanci; mutacija
